| Description | KLK9 Human Pre-designed siRNA Set A contains three designed siRNAs for KLK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components KLK9 siRNA-1: 5 nmol (HPLC) KLK9 siRNA-2: 5 nmol (HPLC) KLK9 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 KLK9 Human Pre-designed siRNA Set A contains three designed siRNAs for KLK9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components KLK9 siRNA-1: 5 nmol (HPLC) KLK9 siRNA-2: 5 nmol (HPLC) KLK9 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | The Leuconostoc GPDH exhibits dual coenzyme specificity, namely NAD and NADP (Olive and Levy, Biochem., 6, 730 730, 1967). When assayed under conditions that are optimal for the particular coenzyme, the ratio of observed catalytic activity is NAD/NADP = 1.8 | Unit Definition One unit will cause a change in A600 of 0.330 per minute at pH 5.7 at 37°C in a 2.0 ml reaction mixture (45 minute assay) | Purity>97% by SDS-PAGE and HPLC analyses.Additional sequence informationFunction N-terminal glycine. Full-length mature chain lacking the signal peptideFunctionHas chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine Purity>97% by SDS-PAGE and HPLC analyses.Additional sequence informationFunction N-terminal glycine. Full-length mature chain lacking the signal peptideFunctionHas chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity.Post-translationalN-terminal processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) are produced by proteolytic cleavage after secretion from peripheral blood monocytes... Read More | Inquire |